Week of May 17th, 2021 | Vol. 10, Issue 20
In This Issue
Featured Headlines
Recent Industry Transactions
Industry Trading Comps
Recent Industry Headlines
Market Reports
Upcoming Events

Quick Links

Contact Information
Managing Director
Business Development

Managing Director
Head of M&A and Capital Advisory

Above is an overview of recent industry M&A activity. For additional information, see the charts below or click on the chart above to download complete transaction tables broken out by industry sub sectors.

For more information about our consumer healthcare JV with The Emerson Group, Daybreak Consumer Care, click here.
Recent Materials Providing Insight Into Healthcare Related Industries
Current M&A Pipeline
Representative Current Retained Sell-Side And Partnering Opportunities
Project Focus
Sell-side | CMO | Liquids and Semi-solids CMO headquartered in North America

Project Trident
Buy-side | Generic Pharma | Manufacturing liquid generics

Project Aspen
Sell-side | CDMO | Multinational CDMO headquartered in US

Project Athena
Sell-side / Licensing | Medical Device | Novel device for pelvic organ prolapse
Barely a week after striking a $2.5 billion special purpose acquisition company deal to go public, Ginkgo Bioworks is going international. In its first move to extend its operations beyond the U.S., the synthetic biology player is acquiring Dutch DNA Biotech, a contract manufacturing organization that makes enzymes, proteins and organic acids using its fungus-based technology. 

Under the deal, Ginkgo will acquire 100% of the Utrecht, Netherlands-based company through a combination of cash and equity, the company said in a statement. “Certain stakeholders” of Dutch DNA will also collect payments later on if the company meets certain technical and commercialization goals, Ginkgo said. It shared no financial details about the deal, which is slated to close in July. 

An Overview of Transactions Within Market Sub-segments
Below are summaries and charts with the past week's transactions from the different healthcare sectors. For a detailed table showing data for each industry transaction click on any of the charts. Total transaction values are provided in USD millions.
Pharma & Biotech
19 transactions totaling $2,583 million
Supplies, Equipment & Services
29 transactions totaling $4,901 million
Healthcare IT & Managed Care
9 transactions totaling $503 million
Healthcare Facilities & Distributors
15 transactions totaling $1,024 million
Pharma & Biotech
41 transactions totaling $2,498 million
Supplies, Equipment & Services
29 transactions totaling $545 million
Healthcare IT & Managed Care
18 transactions totaling $635 million
Healthcare Facilities & Distributors
6 transactions totaling $3,612 million
Pharma & Biotech
24 transactions totaling $2,416 million
Supplies, Equipment & Services
14 transactions totaling $2,381 million
Healthcare IT & Managed Care
0 transactions
Healthcare Facilities & Distributors
0 transactions
A Breakdown of Relevant Trading Multiples
Each week, we provide updated trading comps for leading companies from numerous healthcare sub-sectors.
To the right you will see a high-level breakdown of median revenue and EBITDA multiples for each of the specific sub sectors.

For a complete trading comp analysis (including the individual equities that comprise the sub sectors), click on the table. 

Note: data reflects prior week close.
A Sampling of Relevant Industry Headlines from Last Week
Below are snippets from relevant industry news articles from the past week. For additional information or the article's complete text, click the headline link to view the original publication.
May 13, 2021 - Fierce Healthcare
Cedar offers patient-personalized medical billing and pre-visit technology that includes appointment reminders, digital registration forms and the ability to collect insurance information. But focusing on provider billing only solves "one part of the problem," Otto told Fierce Healthcare.

May 12, 2021 - Contract Pharma
This is Emmes' second acquisition in the past four months, following the acquisition of Neox s.r.o., an EU-based CRO, in December 2020. Neox and Orphan Reach expand Emmes' global reach with their international footprints and add a larger and more diverse set of biopharmaceutical clients.

May 11, 2021 - Fierce Pharma
Viatris comes from a combination of Mylan and Pfizer’s Upjohn generic business, while Organon is built from the women’s health and biosimilar franchises offloaded by Merck & Co. A merger between them “seems logical given similar business model and complementary assets,” Bernstein analyst Ronny Gal wrote in a note to clients.

May 11, 2021 - Contract Pharma
Cambrex has expanded its cGMP analytical testing capabilities at its site in Longmont, CO. Existing space at the site has been repurposed with cutting edge technologies and doubles the footprint of the laboratory operations.
Welcome to Bourne, let's talk.

Since our founding in 2001, Bourne Partners has remained focused on fulfilling the unique needs of established, middle-market healthcare and pharmaceutical companies across the globe. Our track record includes advising middle market companies in healthcare M&A assignments totaling more than $7 billion, and growing companies into successful and well-positioned pharmaceutical enterprises.